Evidence map›Paper›PMID 40261702›Full record

ArticleJCI insight2025

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor.

Xin Li, Maria Rossing, Ana Moisés da Silva, Muthiah Bose, Thorkell Gudjónsson, Jan Benada, Jayashree Thatte, Jens Vilstrup Johansen, Judit Börcsök, Hanneke van der Gulden and 9 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Xin LiBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Maria RossingCenter for Genomic Medicine, Rigshospitalet, and.
Ana Moisés da SilvaDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Muthiah BoseBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Thorkell GudjónssonBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Jan BenadaBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Jayashree ThatteBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Jens Vilstrup JohansenBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Judit BörcsökBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Hanneke van der GuldenDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Ji-Ying SongOncode Institute, Utrecht, Netherlands.
Renée MenezesBiostatistics Centre & Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Asma TajikBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Lucía SenaBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Zoltan SzallasiTranslational Cancer Genomics Group, Danish Cancer Institute, Copenhagen, Denmark.
Morten FrödinBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Jos JonkersDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Finn Cilius NielsenCenter for Genomic Medicine, Rigshospitalet, and.
Claus Storgaard SørensenBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in genome maintenance factors drive sporadic and hereditary breast cancers. Here, we searched for potential drivers based on germline DNA analysis from a cohort consisting of patients with early-onset breast cancer negative for BRCA1/BRCA2 mutations. This revealed candidate genes that subsequently were subjected to RNA interference-based (RNAi-based) phenotype screens to reveal genome integrity effects. We identified several genes with functional roles in genome maintenance, including Glucose-6-Phosphatase Catalytic Subunit 3 (G6PC3), SMC4, and CCDC108. Notably, G6PC3-deficient cells exhibited increased levels of γH2AX and micronuclei formation, along with defects in homologous recombination (HR) repair. Consistent with these observations, G6PC3 was required for the efficient recruitment of BRCA1 to sites of DNA double-strand breaks (DSBs). RNA-Seq analysis revealed that G6PC3 promotes the expression of multiple homologous recombination repair genes, including BRCA1. Through CRISPR-Select functional-genetic phenotype analysis of G6PC3 germline mutations, we identified 2 germline G6PC3 variants displaying partial loss of function. Furthermore, our study demonstrated that G6pc3 deficiency accelerates mammary tumor formation induced by Trp53 loss in mice. In conclusion, our cohort-based functional analysis has unveiled genome maintenance factors and identified G6PC3 as a potential candidate tumor suppressor in breast cancer.

Indexed as

Breast NeoplasmsAnimalsBRCA1 ProteinDNA Breaks, Double-StrandedFemaleGenomic InstabilityGerm-Line MutationHumansMiceRecombinational DNA RepairTumor Suppressor Protein p53BRCA1 ProteinBRCA1 protein, humanTumor Suppressor Protein p53Breast cancerCell biologyClinical ResearchDNA repairGenetic instabilityGenetics

Identifiers

PMID40261702
PMCPMC12220951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.